Skip to main content

Journal Club

Cerebrovascular

Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion

The New England Journal of Medicine | 2021

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1056/NEJMoa2030297

PMID

N/A

PICO

Population

Adults within 6 hours after estimated onset of stroke from basilar-artery occlusion enrolled across 23 centers in 7 countries.

Intervention

Endovascular therapy plus usual medical care.

Comparator

Standard medical care alone.

Outcomes

Ninety-day favorable functional outcome, symptomatic intracranial hemorrhage, and mortality.

Design

Type

Multicenter open-label randomized controlled trial

Randomized

Yes

Multicenter

Yes

Blinded

N/A

Follow-up

90 days

Primary endpoint

Favorable functional outcome defined as modified Rankin Scale score 0 to 3 at 90 days.

Secondary endpoints

  • Symptomatic intracranial hemorrhage within 3 days
  • Mortality at 90 days
  • Other functional outcomes by ordinal modified Rankin analysis

Practice impact

What this means

BASICS was a randomized trial of thrombectomy for basilar-artery occlusion, but it came out neutral: the endovascular group did a bit better numerically, yet the confidence interval still included no real benefit. The clean read is not that thrombectomy failed, but that this particular trial could not settle the question on its own.

Bottom line

BASICS did not prove a statistically significant functional benefit for endovascular therapy in basilar-artery occlusion, so this paper alone should not be treated as definitive support or refutation of thrombectomy.

Strength of evidence

moderate

Recommendation

do not change

Why it matters

  • The point estimate favored thrombectomy, but the confidence interval crossed no effect.
  • Safety and mortality signals were directionally mixed and imprecise.
  • A neutral underpowered trial should not outweigh the rest of the evolving evidence base by itself.

What would change my mind

  • Additional randomized evidence showing a clear, reproducible benefit or lack of benefit in modern basilar-occlusion selection.
  • Pooled individual-patient data demonstrating that BASICS was truly negative even in patients most likely to benefit.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

The trial was open-label and treatment decisions after randomization were visible to clinicians, although the main outcome definition was objective enough to limit some measurement bias.

Confounding

Randomization should reduce baseline confounding, but crossover patterns, evolving thrombectomy practice during the trial, and heterogeneous local workflows could still dilute a true treatment effect.

Missing data

The main concern is not classic loss to follow-up but early trial complexity, including slow recruitment and protocol-era drift during years when thrombectomy technology and selection standards changed.

Multiplicity

The primary analysis was neutral, so secondary and subgroup findings should be viewed as exploratory rather than practice-defining on their own.

Notes

  • This was an international trial across 23 centers in 7 countries.
  • The confidence interval around the primary effect was wide enough that a clinically important benefit could not be excluded.
  • The paper predates later positive basilar-occlusion trials, so it should be interpreted in its time context.

Stats check

NNT

N/A

Effect sizes

  • Favorable 90-day outcome occurred in 44.2% with endovascular therapy versus 37.7% with medical care (risk ratio 1.18, 95% CI 0.92-1.50).
  • Symptomatic intracranial hemorrhage was 4.5% versus 0.7% (risk ratio 6.9, 95% CI 0.9-53.0).
  • Ninety-day mortality was 38.3% versus 43.2% (risk ratio 0.87, 95% CI 0.68-1.12).

Absolute effects

  • The absolute difference in favorable outcome was 6.5 percentage points in favor of endovascular therapy.
  • The absolute mortality difference was 4.9 percentage points in favor of endovascular therapy.
  • Endovascular treatment was started at a median of 4.4 hours after stroke onset.

Concerns

  • The primary result was not statistically significant.
  • Wide confidence intervals mean both meaningful benefit and little benefit remain plausible.
  • The hemorrhage estimate is imprecise because event counts were small.

External validity

Who it applies to

Patients presenting early with basilar-artery occlusion at centers capable of rapid thrombectomy and advanced stroke imaging.

Who it does not

Patients far outside the trial window, those without access to experienced thrombectomy teams, or populations selected under later-generation basilar-occlusion criteria.

Generalizability notes

  • The international multicenter design improves real-world relevance.
  • Because thrombectomy practice evolved during the trial, the results may underestimate benefit in highly selected modern workflows.
  • The paper is most applicable as a neutral-to-suggestive trial rather than a final answer.

Evidence trace

Source trace and metadata

Citations (4)

claim_id

methods_critique.confounding

locator

p. 2

claim_id

stats_check.effect_sizes

locator

p. 1

claim_id

stats_check.absolute_effects

locator

p. 1

claim_id

practice_impact.bottom_line

locator

p. 1

Metadata

Generated at

2026-03-08T15:20:00-05:00

Version

manual-pdf-repair-v1